Fuzapladib sodium (C09-1133-917)

Fuzapladib sodium (IS-741 sodium) is a potent and orally active phospholipase A2 inhibitor. Fuzapladib sodium can block the adhesion of inflammatory cells to microvascular endothelial cells, inhibits the infiltration of neutrophils into the pancreas or acute pancreatitis, and has anti-acute pancreatitis effects.In VitroFuzapladib sodium (IS-741 sodium) (1 μM, 3 h) can significantly inhibit the adhesion of HL-60 cells to HUVEC under the stimulation of lipopolysaccharide. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoFuzapladib sodium (IS-741 sodium) (p.o., 50 mg/kg, 7 days) inhibits neutrophil infiltration into inflamed lesions, and is effective for attenuating rat TNBS ileitis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: RatsDosage: 50 mg/kg Administration: P.o.; for 7 days Result: Significantly reduced myeloperoxidase (MPO) activity and mucosal IL-8 levels in rat ileum, reduced polymorphonuclear cells and Mac-1 positivity Infiltration of cells into inflammatory lesions, effectively alleviated trinitrobenzenesulfonic acid (TNBS)-induced ileitis.Form:Solid. Specification: 0.99 Molecular Formula: C15H20F3N3NaO3S Molecular Weight: 402.39 PubChem CID: 23711649 Isomeric SMILES: CCS(=O)(=O)[N-]C1=C(C=C(C=N1)C(F)(F)F)NC(=O)C2CCCCC2.[Na+]